Today: 9 November 2025
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Skip the TSA Line: Airports Use Your Face as Your Boarding Pass

Skip the TSA Line: Airports Use Your Face as Your Boarding Pass

Sources: News reports and expert interviews through Oct. 12, 2025 (Travel + Leisure travelandleisure.com, SF Chronicle sfchronicle.com, BiometricUpdate biometricupdate.com, IDTechWire idtechwire.com, Reuters reuters.com reuters.com, TS2.tech ts2.tech ts2.tech, MarketBeat marketbeat.com). All citations link to published articles and official statements.
12 October 2025
 ·  ·  ·  ·  · 
Budget Airline Bonanza: Frontier & Allegiant Expand Routes as Travel Demand Skyrockets

Budget Airline Bonanza: Frontier & Allegiant Expand Routes as Travel Demand Skyrockets

Strong Demand Lifts Budget Carriers Despite economic worries, travel bookings are robust. U.S. travel forecasts show domestic leisure spending rising about 1.9% in 2025 ustravel.org. According to the U.S. Travel Association, Americans have “continued to prioritize travel” even with inflation concerns ustravel.org. Major carriers report booming bookings, especially for premium seats and long-haul routes. For example, Delta and United see surging business and first-class travel ts2.tech reuters.com. As Delta’s management noted, a six-week spike in corporate travel has finally returned ts2.tech. This demand surge has coincided with a pullback in capacity. Spirit Airlines recently filed for bankruptcy and is slashing
12 October 2025
 ·  ·  ·  ·  ·  · 
Airline Stocks Face Turbulence: JetBlue Crashes 41% and Experts Sound Alarm

Airline Stocks Face Turbulence: JetBlue Crashes 41% and Experts Sound Alarm

JetBlue’s Slide and Ratings JetBlue’s stock has been battered recently. Despite raising its Q3 guidance in September (strong late-summer bookings and cheaper fuel allowed JetBlue to tighten capacity and increase revenue forecasts flightglobal.com flightglobal.com), investors remain skeptical. The airline’s Jul–Sep earnings showed a loss of $0.16 per share (worse than many peers) marketbeat.com. JetBlue’s heavy debt load and sub‐1x price/sales make it vulnerable as yields soften. Credit and equity analysts are cautious: Weiss Ratings’ Oct 9 report gave JBLU a “sell (D-)” rating marketbeat.com. MarketBeat notes that 7 analysts now rate JBLU Hold and 5 rate Sell, yielding a consensus
12 October 2025
 ·  ·  ·  · 
Trump Axes 6.2GW “Vegas-Sized” Solar Farm in Nevada – Renewable Energy Industry Reels

Trump Axes 6.2GW “Vegas-Sized” Solar Farm in Nevada – Renewable Energy Industry Reels

BLM on Oct 10 listed the Esmeralda 7 solar project in Nevada as “cancelled” energyconnects.com theguardian.com. The massive project (seven contiguous solar farms on ~185 sq mi of public land) would have generated ~6,200 MW – enough for nearly 2 million homes pv-magazine-usa.com theguardian.com. Interior Secretary Doug Burgum’s Trump administration said developers can now submit individual proposals instead of one programmatic EIS energyconnects.com electrek.co. Conservationists and some locals celebrated the cancellation, while clean‑energy advocates (NRDC, SEIA, EDF) warned it’s a blatant rollback of renewables: NRDC’s Kabir Green calls it “unfettered obstruction” of clean-energy projects pv-magazine-usa.com. The cancellation comes amid a broader Trump‐era push against renewables:
12 October 2025
 ·  ·  ·  ·  · 
Circle (CRCL) Stock’s Wild Ride: Stablecoin Boom, Volatile Swings & 2025 Outlook

Circle (CRCL) Stock’s Wild Ride: Stablecoin Boom, Volatile Swings & 2025 Outlook

Recent Developments & News (October 2025) October 2025 has been eventful for Circle, with major partnership news and stock volatility grabbing headlines. On Sept 30, Circle revealed a collaboration with Deutsche Börse, one of the world’s largest market infrastructure providers, to integrate its stablecoins into traditional capital markets ts2.tech. This deal will explore listing USDC/EURC on Deutsche Börse’s trading platforms and using Circle’s coins in settlement and custody via the exchange’s networks ts2.tech. Around the same time, Circle announced fintech firms Arf and Huma joined its Circle Payments Network to offer credit and liquidity services in USDC ts2.tech – part
11 October 2025
 ·  ·  ·  ·  · 
Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Uranium Energy Corp (UEC) Stock Skyrockets on Nuclear Boom – Key Facts & Outlook

Overview of Uranium Energy Corp (UEC) Uranium Energy Corp is a U.S.-based uranium mining and exploration company founded in 2003 (NYSE American: UEC). Headquartered in Corpus Christi, Texas, UEC has become “America’s largest and fastest growing supplier of uranium” for nuclear energy prnewswire.com. The company’s business model focuses on low-cost in-situ recovery (ISR) mining in the United States and high-grade conventional uranium projects in Canada prnewswire.com. This two-pronged approach lets UEC rapidly develop domestic uranium sources while also holding stakes in some of the world’s richest uranium districts. UEC operates on a “hub-and-spoke” strategy for ISR production. It has three
11 October 2025
 ·  ·  ·  ·  · 
NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease newamsterdampharma.com. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion newamsterdampharma.com. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 newamsterdampharma.com. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team
11 October 2025
 ·  ·  ·  ·  · 
Broadcom’s AI Windfall: Inside AVGO’s Trillion-Dollar Surge, $10B Chip Deal & 2025 Outlook

Broadcom’s AI Windfall: Inside AVGO’s Trillion-Dollar Surge, $10B Chip Deal & 2025 Outlook

Broadcom’s Financial Performance and Stock Trajectory Broadcom’s stock has been on a meteoric rise in 2023–2025, riding the twin waves of AI chip euphoria and strategic acquisitions. Even after the recent market volatility, AVGO is up dramatically year-to-date and over the past 12 months. At the start of 2024, Broadcom’s market cap was around $300 B; by October 2025 it ballooned past $1.5 trillion ts2.tech. The company’s decision to enact a 10:1 stock split (in February 2024) helped spur retail interest, while its fundamental performance justified the climb. Earnings momentum has been strong. In fiscal 2024 (ended Oct 2024), Broadcom’s revenue was
11 October 2025
 ·  ·  ·  ·  · 
TSMC’s AI-Fueled Surge: Record Highs, Big Risks, and Bold Predictions (Oct 2025 Update)

TSMC’s AI-Fueled Surge: Record Highs, Big Risks, and Bold Predictions (Oct 2025 Update)

TSMC Stock Soars on AI Boom TSMC (Taiwan Semiconductor Manufacturing Co.) is riding a wave of investor enthusiasm as of October 2025. Its Taipei-listed shares hit record highs this month – reaching NT$1,370 on Oct 2 (about $43 USD per share) ts2.tech – and the U.S. ADR (NYSE: TSM) likewise surged to all-time highs, briefly trading above $300. In fact, TSMC’s U.S. stock spiked to an intraday $307 on Oct 7 amid frenzied buying ts2.tech. Even after a bit of profit-taking, TSMC hovers around the mid-$290s per share as of Oct 11, reflecting a dramatic upswing from roughly ~$200 at
11 October 2025
 ·  ·  ·  ·  · 
Trump Media’s Wild Ride: DJT Stock Soars on Politics, Crypto & Controversy

Trump Media’s Wild Ride: DJT Stock Soars on Politics, Crypto & Controversy

Stock Price and Recent Performance As of mid-October 2025, DJT stock hovers around $15–$16, a far cry from its highs. It closed at $15.97 on October 10, 2025 investing.com investing.com, continuing a downward trend. The stock has lost roughly half its value in 2025 alone, and over the past year it’s down about 32% tickernerd.com. For context, DJT’s 52-week range spans from $15.42 up to $54.68 investing.com tickernerd.com – meaning it has collapsed about 70% from its peak. That peak came amid tremendous enthusiasm earlier in Trump’s presidential term, but momentum has since faded. Wild volatility is a hallmark of
11 October 2025
 ·  ·  ·  ·  · 
Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

Robinhood’s Wild 2025 Ride: HOOD Stock Skyrockets 200%, Plunges 9% in a Day – What’s Next?

HOOD Stock Price and Recent Performance Robinhood’s stock has been on a rollercoaster in 2025. After starting the year at much lower levels, HOOD nearly tripled in value by early October. On October 6, shares hit a record intra-week high around $153. But by the week’s end, the stock pulled back sharply, closing at $138.96 on Oct 10 after an 8.9% single-day plunge ts2.tech. (The Oct 10 drop coincided with a broader market selloff sparked by renewed U.S.–China trade war fears, which particularly hit high-growth tech stocks ts2.tech.) Even after the pullback, Robinhood remains up over 200% year-to-date, vastly outperforming
11 October 2025
 ·  ·  ·  ·  · 
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

(Source: Nasdaq/GlobeNewswire, Reuters, TipRanks, Finviz, company filings.) Company Overview: Rare Disease Focus and Pipeline Progress Quoin Pharmaceuticals Ltd. is a clinical-stage biotech specializing in rare dermatological diseases. Headquartered in Ashburn, VA, Quoin’s mission is to deliver the first approved therapies for conditions that currently have none. “We remain fully focused on delivering the first approved therapy for Netherton Syndrome,” said CEO Dr. Michael Myers globenewswire.com. The company’s pipeline comprises three main product candidates targeting multiple orphan indications finviz.com: Until recently, Quoin had additional assets (QRX004 for epidermolysis bullosa, and QRX007 for Netherton) but shelved those programs in mid-2025 to concentrate
11 October 2025
 ·  ·  ·  ·  · 
1 … 79 80 81 82 83 … 170
Go toTop